Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Techniques for segmentation include determining an edge of voxels in a range associated with a target object. A center voxel is determined. Target size is determined based on the center voxel. In some embodiments, edges near the center are suppressed, markers are determined based on the center, and an initial boundary is determined using a watershed transform. Some embodiments include determining multiple rays originating at the center in 3D, and determining adjacent rays for each. In some embodiments, a 2D field of amplitudes is determined on a first dimension for distance along a ray and a second dimension for successive rays in order. An initial boundary is determined based on a path of minimum cost to connect each ray. In some embodiments, active contouring is performed using a novel term to refine the initial boundary. In some embodiments, boundaries of part-solid target objects are refined using Markov models.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.